Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 10/2017

01.10.2017 | Neuroimaging (N Pavese, Section Editor)

Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment

verfasst von: Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Apathy, depression, and anxiety are among the most important non-motor signs of Parkinson’s disease (PD). This may be encountered at early stages of illness and represent a major source of burden. Understanding their pathophysiology is a major prerequisite for efficient therapeutic strategies. Anatomical and metabolic imaging studies have enabled a breakthrough by demonstrating that widespread abnormalities within the limbic circuits notably the orbitofrontal and anterior cingulate cortices, amygdala, thalamus, and ventral striatum are involved in the pathophysiology of depression, anxiety, and apathy in PD. Functional imaging has further shown that mesolimbic dopaminergic but also serotonergic lesions play a major role in the mechanisms of these three neuropsychiatric manifestations, which has direct therapeutic implications.
Literatur
1.
Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: neurobiological basis. Mov Disord. 2016;31(8):1103–13.CrossRefPubMed
2.
Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30:121–7.CrossRefPubMed
3.
4.
Matsui H, Nishinaka K, Oda M, Niikawa H, Komatsu K, Kubori T, et al. Depression in Parkinson’s disease. Diffusion tensor imaging study. J Neurol. 2007;254:1170–3.CrossRefPubMed
5.
Feldmann A, Illes Z, Kosztolanyi P, Illes E, Mike A, Kover F, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord. 2008;23:42–6.CrossRefPubMed
6.
Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75:857–63.CrossRefPubMed
7.
• Skidmore FM, Yang M, Baxter L, von Deneen K, Collingwood J, He G, et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. NeuroImage. 2013;81:484–95. Resting state fMRI study illustrating the complexicity and differences of brain activity changes responsible for apathy and depression in PD. CrossRefPubMed
8.
Surdhar I, Gee M, Bouchard T, Coupland N, Malykhin N, Camicioli R. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson’s disease with mild depressive symptoms. Parkinsonism Relat Disord. 2012;18:809–13.CrossRefPubMed
9.
van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA. Depressive symptoms in Parkinson’s disease are related to decreased hippocampus and amygdala volume. Mov Disord. 2015;30:245–52.CrossRefPubMed
10.
• Vriend C, Boedhoe PS, Rutten S, Berendse HW, van der Werf YD, van den Heuvel OA. A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatry. 2016;87(5):493–500. Recent MRI study underlying the role of amygdala in neuropsychiatric symptoms in PD. CrossRefPubMed
11.
• Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, Maniscalco JS, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord. 2013;35:183–96. FDG PET study highlighting the widespread metabolic disorders observed in relation to neuropsychiatric manifestations in PD. CrossRefPubMed
12.
Huang P, Xuan M, Gu Q, Yu X, Xu X, Luo W, et al. Abnormal amygdala function in Parkinson’s disease patients and its relationship to depression. J Affect Disord. 2015;183:263–268.58.CrossRefPubMed
13.
Hu X, Song X, Yuan Y, Li E, Liu J, Liu W, et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease. Mov Disord. 2015;30:238–44.CrossRefPubMed
14.
O'Callaghan C, Shine JM, Lewis SJ, Hornberger M. Neuropsychiatric symptoms in Parkinson’s disease: fronto-striatal atrophy contributions. Parkinsonism Relat Disord. 2014;20:867–72.CrossRefPubMed
15.
Deng X, Tang CY, Zhang J, Zhu L, Xie ZC, Gong HH, et al. The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson's disease. Neurosci Lett. 2016;633:279–89.CrossRefPubMed
16.
Huang P, Lou Y, Xuan M, Gu Q, Guan X, Xu X, et al. Cortical abnormalities in Parkinson’s disease patients and relationship to depression: a surface-based morphometry study. Psychiatry Res. 2016;250:24–8.CrossRefPubMed
17.
Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol. 1990;28:57–64.CrossRefPubMed
18.
Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry. 2002;159:746–54.CrossRefPubMed
19.
Luo C, Chen Q, Song W, Chen K, Guo X, Yang J, et al. Resting-state fMRI study on drug-naive patients with Parkinson’s disease and with depression. J Neurol Neurosurg Psychiatry. 2014;85:675–83.CrossRefPubMed
20.
Schultz W, Tremblay L, Hollerman JR. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb Cortex. 2000;10(3):272–83.CrossRefPubMed
21.
Amemori K, Graybiel AM. Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making. Nat Neurosci. 2012;15(5):776–85.CrossRefPubMedPubMedCentral
22.
Wen X, Wu X, Liu J, Li K, Yao L. Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson’s disease: a resting-state functional magnetic resonance imaging study. PLoS One. 2013;8:e63691.CrossRefPubMedPubMedCentral
23.
Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord. 2006;21(8):1169–74.CrossRefPubMed
24.
Luo C, Song W, Chen Q, Yang J, Gong Q, Shang HF. Cortical thinning in drug-naive Parkinson’s disease patients with depression. J Neurol. 2016;263(10):2114–9.CrossRefPubMed
25.
Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010;25:2318–25.CrossRefPubMed
26.
Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–82.PubMed
27.
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–60.CrossRefPubMed
28.
Cardoso EF, Maia FM, Fregni F, Myczkowski ML, Melo LM, Sato JR, et al. Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. NeuroImage. 2009;47:467–72.CrossRefPubMed
29.
Li W, Liu J, Skidmore F, Liu Y, Tian J, Li K. White matter microstructure changes in the thalamus in Parkinson disease with depression: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol. 2010;31:1861–6.CrossRefPubMed
30.
Sheng K, Fang W, Su M, Li R, Zou D, Han Y, et al. Altered spontaneous brain activity in patients with Parkinson’s disease accompanied by depressive symptoms, as revealed by regional homogeneity and functional connectivity in the prefrontal-limbic system. PLoS One. 2014;9:e84705.CrossRefPubMedPubMedCentral
31.
Hu X, Song X, Li E, Liu J, Yuan Y, Liu W, et al. Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS One. 2015;10(7):e0131133.CrossRefPubMedPubMedCentral
32.
Lou Y, Huang P, Li D, Cen Z, Wang B, Gao J, et al. Altered brain network centrality in depressed Parkinson’s disease patients. Mov Disord. 2015;30(13):1777–84.CrossRefPubMed
33.
Huang P, Xu X, Gu Q, Xuan M, Yu X, Luo W, et al. Disrupted white matter integrity in depressed versus non-depressed Parkinson’s disease patients: a tract-based spatial statistics study. J Neurol Sci. 2014;346(1–2):145–8.CrossRefPubMed
34.
Le Jeune F, Drapier D, Bourguignon A, Péron J, Mesbah H, Drapier S, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009;73:1746–51.CrossRefPubMed
35.
Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79:1155–60.CrossRefPubMed
36.
• Carriere N, Besson P, Dujardin K, Duhamel A, Defebvre L, Delmaire C, et al. Apathy in Parkinson’s disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. Mov Disord. 2014;29:897–903. MRI study underlying morphological abnormalities of the ventral striatum (a key area for motivational processes) in apathetic PD patients. CrossRefPubMed
37.
Robert GH, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Preoperative factors of apathy in subthalamic stimulated Parkinson disease: a PET study. Neurology. 2014;83:1620–6.CrossRefPubMed
38.
Gesquière-Dando A, Guedj E, Loundou A, Carron R, Witjas T, Fluchère F, et al. A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation. Mov Disord. 2015;30(13):1767–76.CrossRefPubMed
39.
Baggio HC, Segura B, Garrido-Millan JL, Marti MJ, Compta Y, Valldeoriola F, et al. Resting-state frontostriatal functional connectivity in Parkinson’s disease-related apathy. Mov Disord. 2015;30:671–9.CrossRefPubMed
40.
Lawrence AD, Goerendt IK, Brooks DJ. Apathy blunts neural response to money in Parkinson's disease. Soc Neurosci. 2011;6(5–6):653–62. 122CrossRefPubMed
41.
Levita L, Hoskin R, Champi S. Avoidance of harm and anxiety: a role for the nucleus accumbens. NeuroImage. 2012;62(1):189–98.CrossRefPubMed
42.
•• Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133:1111–27. Large clinical and PET study demonstrating different profile of mesolimbic dopaminergic denervation responsible for different risk of developping apathy after STN stimulation in PD. CrossRefPubMed
43.
Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed
44.
Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25:3132–6.CrossRefPubMed
45.
Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–32.PubMed
46.
Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23(11):1580–7.CrossRefPubMed
47.
Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.CrossRefPubMed
48.
Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18:1034–8.CrossRefPubMed
49.
•• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–22. First study demonstrating a link between apathy, depression and anxiety and dopaminergic lesions within limbic network. CrossRefPubMed
50.
Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology. 2010;211:27–31.CrossRefPubMed
51.
Moriyama TS, Felicio AC, Chagas MH, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310:53–7.CrossRefPubMed
52.
Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, et al. Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. Eur J Neurol. 2013;20:480–5.CrossRefPubMed
53.
Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain. 2009;132:1366–75.CrossRefPubMed
54.
Rektorova I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.CrossRefPubMed
55.
•• Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80. Seminal paper demonstrating the response of depression to dopamine agonist in PD patients. CrossRefPubMed
56.
Ray Chaudhuri K, Martinez-Martin P, Antonini A, Antonini A, Brown RG, Friedman JH, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660–5.CrossRefPubMed
57.
Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22:1400–7.CrossRefPubMed
58.
Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013;8:e79510.CrossRefPubMedPubMedCentral
59.
Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016;17(11):1453–61.CrossRefPubMed
60.
Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic review. Drugs. 2011;71(3):273–86.CrossRefPubMed
61.
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63. First description of dopamine withdrawal syndrome after dopamine agonists arrest in PD. CrossRefPubMed
62.
Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138:2964–297.CrossRefPubMed
63.
•• Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776–80. This PET study highlighted the role of serotonergic lesions in depression in PD. CrossRefPubMed
64.
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–7.CrossRefPubMed
65.
Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol. 2007;14(5):523–8.CrossRefPubMed
66.
Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord. 2012;27:84–9.CrossRefPubMed
67.
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med. 2012;4:128ra141.CrossRef
68.
•• Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139(Pt 9):2486–502. First study demonstrating in de novo PD patients a major relationship between serotonergic lesions, apathy, depression and anxiety, while the role of dopaminergic lesions appears less prominent. CrossRefPubMed
69.
Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, et al. Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry. 1997;63(5):590–6.CrossRefPubMedPubMedCentral
70.
Berg D, Supprian T, Hofmann E, Zeiler B, Jäger A, Lange KW, et al. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol. 1999;246(12):1186–93.CrossRefPubMed
71.
Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord. 1997;12(5):756–9.CrossRefPubMed
72.
Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–8.CrossRefPubMed
73.
Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord. 2000;15(5):986–9.CrossRefPubMed
74.
Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006;21:1119–22.CrossRefPubMed
75.
Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.CrossRefPubMed
76.
Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–7.CrossRefPubMed
77.
Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–36.CrossRefPubMedPubMedCentral
78.
Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–55.CrossRefPubMedPubMedCentral
79.
• Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78(6):641–3. First study linking depression and cholinergic lesions in PD. CrossRefPubMedPubMedCentral
80.
Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord. 2015;8(2):98–102.CrossRefPubMedPubMedCentral
81.
Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2015;21:489–93.CrossRefPubMed
82.
Czernecki V, Schupbach M, Yaici S, Lévy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964–9.CrossRefPubMed
83.
Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136:1568–77.CrossRefPubMed
84.
Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2016;23:62–5.CrossRefPubMed
85.
• Sgambato-Faure V, Tremblay L. Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states. J Neural Transm (Vienna). 2017. doi:10.​1007/​s00702-017-1693-z. Excellent review on the complex role of serotonergic and dopaminergic system on motor and non motor manifestations.
86.
• Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85:668–74. First study demonstrating an impact of anticholinesterase drug on apathy in PD. CrossRefPubMed
Metadaten
Titel
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
verfasst von
Stephane Thobois
Stephane Prange
Véronique Sgambato-Faure
Léon Tremblay
Emmanuel Broussolle
Publikationsdatum
01.10.2017
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 10/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0788-0

Weitere Artikel der Ausgabe 10/2017

Current Neurology and Neuroscience Reports 10/2017 Zur Ausgabe

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Optical Coherence Tomography to Differentiate Papilledema from Pseudopapilledema

Stroke (H Diener, Section Editor)

Carotid Artery Stenosis: Medical Therapy, Surgery, and Stenting

Stroke (H Diener, Section Editor)

Management of Spontaneous Intracerebral Hemorrhage

Stroke (H Diener, Section Editor)

DVT Prevention in Stroke

Nerve and Muscle (L H Weimer, Section Editor)

Sensory Neuronopathies

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise